Pilot application of iTRAQ to the retinal disease Macular Telangiectasia.

12:48 EDT 2nd September 2014 | BioPortfolio

Summary of "Pilot application of iTRAQ to the retinal disease Macular Telangiectasia."

We used the comparative proteomic technique iTRAQ coupled with offline 2DLC-MS/MS to analyze a rare specimen of the poorly understood, potentially blinding ophthalmic condition, Macular Telangiectasia type 2 (MacTel type 2). We refined the technique using an internal standard consisting of pooled samples for each iTRAQ experiment to allow for multiple comparisons between different regions of the retina and different tissue donors. A total of 594 non-redundant proteins were identified in the retina and 168 in the vitreous, of which approximately half were found in significantly different abundance in the various comparisons made. The most prominent differences were found within the glycolytic pathway, where 8 proteins were reduced in the diseased macula compared with peripheral retina of the same eye, and 10 were also reduced in comparison with the macula of a control eye. Furthermore, Müller cell-associated proteins, including GFAP, VIME and GLNA, were also reduced in the diseased macula, consistent with a link between the glycolytic pathway and Müller cells. These changes were validated by Western blotting and immunohistochemical studies. Proteomic analysis of the vitreous revealed an increase of proteins that were reduced in the retina. This supports proteomic analysis of the more easily available vitreous, which may reveal retina-specific protein changes associated with disease. Furthermore, our study has highlighted changes in the glycolytic pathway as a possible component of MacTel type 2 pathobiology.

Affiliation

Journal Details

This article was published in the following journal.

Name: Journal of proteome research
ISSN: 1535-3907
Pages:

Links

PubMed Articles [21675 Associated PubMed Articles listed on BioPortfolio]

CHOROIDAL THICKNESS IN MACULAR TELANGIECTASIA TYPE 2.

To assess the choroidal thickness changes in eyes with macular telangiectasia Type 2 and their relationship with the integrity of outer retinal structures and visual acuity.

FIRST SYMPTOMS AND THEIR AGE OF ONSET IN MACULAR TELANGIECTASIA TYPE 2.

To investigate the first symptoms and their age of onset in a large cohort of patients with macular telangiectasia type 2.

Multiple extra macular branch retinal vein occlusions in hyperhomocysteinemia.

Hyperhomocysteinemia is a well-known modifiable risk factor for thromboembolism. Retinal vascular occlusion in patients having hyperhomocysteinemia is a known entity, particularly in young patients. H...

Ischemic Retinal Vasculitis and Its Management.

Ischemic retinal vasculitis is an inflammation of retinal blood vessels associated with vascular occlusion and subsequent retinal hypoperfusion. It can cause visual loss secondary to macular ischemia,...

Delayed macular hole formation after demarcation laser photocoagulation for subclinical retinal detachment.

The purpose of this paper is to report a series of macular holes that developed after demarcation laser photocoagulation for subclinical retinal detachments. This observational case series consists of...

Clinical Trials [3647 Associated Clinical Trials listed on BioPortfolio]

Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia

Idiopathic Macular Telangiectasia is characterized by incompetent and dilated retinal capillaries in the foveolar region of unknown cause for retinal telangiectasia. In Idiopathic Macular...

Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)

The purpose of this study is to investigate if a new drug called ranibizumab is effective to treat a rare bilateral disease of the macula: type 2 idiopathic macular telangiectasia (type 2 ...

Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.

The long-term goal is to show that retinal transplantation can help to prevent blindness and to restore eyesight in patients with dry age related macular degeneration.

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)

The primary objective of this pilot study is to compare the functional and anatomic outcomes of chronic macular edema secondary to branch retinal vein occlusion (BRVO) treated with argon l...

Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema

This pilot study aims to establish that treatment with near infrared light (NIR) reduces diabetic macular oedema in patients suffering diabetic retinopathy by exerting a positive beneficia...

Medical and Biotech [MESH] Definitions

Specialized ophthalmic technique used in the surgical repair and or treatment of disorders that include retinal tears or detachment; MACULAR HOLES; hereditary retinal disease; AIDS-related retinal infections; ocular tumors; MACULAR DEGENERATION; DIABETIC RETINOPATHY; and UVEITIS.

Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)

Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.

A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)

A form of MACULAR DEGENERATION also known as dry macular degeneration marked by occurrence of a well-defined progressive lesion or atrophy in the central part of the RETINA called the MACULA LUTEA. It is distinguishable from WET MACULAR DEGENERATION in that the latter involves neovascular exudates.

Search BioPortfolio:
Advertisement

Relevant Topic

Ophthalmology
Latest News Clinical Trials Research Drugs Reports Corporate
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...

Advertisement

Searches Linking to this Article